AveXis Company Profile (NASDAQ:AVXS)

AveXis trades on the NASDAQ under the ticker symbol "AVXS."

AveXis, Inc. (NASDAQ:AVXS) issued its quarterly earnings data on Thursday, May, 11th. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.95) by $0.13. During the same quarter in the previous year, the company earned ($1.24) EPS. View AveXis' Earnings History.

AveXis is scheduled to release their next quarterly earnings announcement on Wednesday, August, 9th 2017. View Earnings Estimates for AveXis.

8 analysts have issued 1-year price targets for AveXis' shares. Their forecasts range from $65.00 to $108.00. On average, they anticipate AveXis' stock price to reach $93.83 in the next twelve months. View Analyst Ratings for AveXis.

Here are some recent quotes from research analysts about AveXis stock:

• 1. According to Zacks Investment Research, "AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company's product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant mortality. AveXis, Inc. is headquartered in Bannockburn, Illinois. " (7/13/2017)
• 2. Jefferies Group LLC analysts commented, "Final data from AVXS-101 in SMA T1 reported that all pts in both cohorts were event free at 13.6 mo of age compared to 25% expected via natural history, the primary EP. Motor milestones were achieved with 9 pts sitting ' 5 secs and 2 pts walking independently. We have lowered our EU T1 risk adj to 15% and began including SMA T2 into our valuation with a 75% risk adj. We reiterate our Buy rating and raise our PT to $92." (3/17/2017)
• 3. Goldman Sachs Group, Inc. (The) analysts commented, "AVXS reported compelling gene therapy AVXS-101 Ph1 final results in spinal muscular atrophy (SMA, genetic neuromuscular disorder) Type I for all patients >13.6 months of age. The data continues to impress ' event-free survival (EFS, death or permanent ventilation) remains 100% in the 12 patients in the high dose therapeutic and notably, in the 3 non-therapeutic cohort as of 1/20. These results are remarkably better than the disease natural history of SMA Type I that suggests 25% EFS at 13.6 months. CHOP INTEND (motor function) and milestone improvements remain intact, with mean increase from baseline of +24.7 (vs. +24.8 prior) in the therapeutic dose vs. -10.5/yr per natural history. 11 (92%) patients are sitting unassisted (by definition, SMA Type I patients never sit unassisted), 9 (75%) rolling over, 2 (17%) standing alone and 2 (17%) walking independently, in line with prior 3m data. On the safety front, SAEs remain restricted to prior asymptomatic liver enzyme elevations which resolved with steroids. We look to: (1) the May 1 FDA meeting (vs. Mar) to discuss the manufacturing (CMC) outlook and June update post receipt of minutes; and (2) an end-of-Ph1 meeting with the FDA in 2Q/3Q to discuss a potential accelerated approval, which would provide upside to our estimates (we assume a 2020 launch on Ph3 data, GSe peak sales of $927mn)." (3/17/2017)
• 4. Chardan Capital analysts commented, "On 23 December 2016, partners Biogen (NASDAQ: BIIB) and Ionis Pharmaceuticals (NASDAQ: IONS)), announced the US FDA approved Spinraza (nusinersen), a chronically-administered SMN2 antisense oligonucleotide for the treatment of spinal muscular atrophy (SMA) types 1 to 3. As discussed in our 27 December 2016 note, on efficacy, Figure 1 of the Spinraza label shows that 23% of SMA type 1 patients taking Spinraza died compared to 43% of untreated patients. We compare this to the phase I trial of AAV-based gene therapy (GT) AVXS-101 (a one-time treatment) from AveXis (Buy), where no SMA type 1 patients so far have died. On safety, as discussed in our 17 January 2017 industry note, the Spinraza label states that 11% of patients developed a platelet level below the lower limit of normal, compared to 0% of patients under sham treatment. Furthermore, as covered in both our 23 January 2017 industry note and in today's accompanying industry note, "Spinraza FDA review confirms our concerns of antisense platelet class effects", both Anthem Healthcare (unrated) and the FDA have expressed concerns regarding the safety of Spinraza."He added, "Considering the above efficacy and safety issues for Spinraza relative to AVXS-101, we reiterate our AVXS Buy rating, make AVXS a Chardan top pick for 2017, and increase our AVXS PT from $85 to $100 (+18%). We also open a pair trade of AVXS (long) and IONS (short), on the increasing potential for 1) AVXS-101 use in SMA types 2 and 3, likely at Spinraza's expense, and 2) Spinraza to increase the size of the SMA market ahead of an AVXS-101 launch." (1/26/2017)

Some companies that are related to AveXis include bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), Beigene Ltd (BGNE), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH), China Biologic Products (CBPO), Agios Pharmaceuticals (AGIO), Prothena Corporation PLC (PRTA), Axovant Sciences (AXON), Sarepta Therapeutics (SRPT), Spark Therapeutics (ONCE), Aerie Pharmaceuticals (AERI), Loxo Oncology (LOXO), Halozyme Therapeutics (HALO) and Radius Health (RDUS).

AveXis' management team includes the folowing people:

• Daniel G. Welch, Independent Chairman of the Board
• Sean Patrick Nolan, President, Chief Executive Officer, Director
• Thomas J. Dee, Chief Financial Officer, Senior Vice President
• Lori J. Smith, Chief Human Resource Officer, Senior Vice President
• Michael Johannesen, Senior Vice President, Chief Compliance Officer, General Counsel
• Andrew F. Knudten, Senior Vice President - Manufacturing and Supply Chain
• James J. L'Italien Ph.D., Senior Vice President - Chief Regulatory and Quality Officer
• Rick Modi, Senior Vice President, Chief Business Officer
• Sukumar Nagendran, Senior Vice President and Chief Medical Officer
• R. A. Session II, Senior Vice President - Corporate Strategy and Project Management

(AVXS) raised $86 million in an IPO on Thursday, February 11th 2016. The company issued 4,300,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and BMO Capital Markets and Chardan were co-managers.

AveXis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FLYNN JAMES E (8.10%) and Bank of Montreal Can (0.11%). Company insiders that own AveXis stock include Bong Y Koh, James E Flynn, Paul B Manning and Sukumar Nagendran. View Institutional Ownership Trends for AveXis.

AveXis' stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have bought AveXis stock in the last two years include Bong Y Koh and James E Flynn. View Insider Buying and Selling for AveXis.

Shares of AveXis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of AveXis stock can currently be purchased for approximately $83.65.